Effectdossier · gearchiveerd kwartaal
ACRS
Aclaris Therapeutics, Inc. · Healthcare · Biotechnology
17Gevolgde houders
+1Δ houders
36.82MGehouden aandelen
$69.96MGerapporteerde waarde
+1Nieuwe posities
−0Uitstappen
Momentum-inputs (vergelijkbare managers):
breedte van houders +6.2% ·
aandelenstroom -17.7% ·
netto nieuwe posities +5.9%
— formule
Versnippering van eigendom — meer houders, kleinere totale positie
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
Eigendom in de tijd
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 61 | -2 | 42.13M | $222.66M | +3 | −5 |
| Q1 2026 | 65 | -2 | 41.75M | $156.42M | +5 | −7 |
| Q4 2025 | 67 | +2 | 40.44M | $121.72M | +2 | — |
| Q3 2025 | 17 | +1 | 36.82M | $69.96M | +1 | — |
| Q2 2025 | 13 | 0 | 38.17M | $54.21M | — | — |
| Q1 2025 | 10 | 0 | 23.63M | $36.15M | — | — |
| Q4 2024 | 10 | +2 | 20.49M | $50.82M | +2 | — |
| Q3 2024 | 7 | -1 | 10.01M | $11.51M | — | −1 |
| Q2 2024 | 8 | — | 10.87M | $11.95M | — | — |
Wie het bezit · Q3 2025
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passief) | 6.52M | -2.2% | $12.38M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | The Vanguard Group ✦ (passief) | 6.52M | -2.2% | $12.38M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | The Vanguard Group ✦ (passief) | 6.52M | -2.2% | $12.38M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | BlackRock ✦ (passief) | 5.69M | +3.2% | $10.81M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | BlackRock ✦ (passief) | 5.69M | +3.2% | $10.81M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | BlackRock ✦ (passief) | 5.69M | +3.2% | $10.81M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | BlackRock ✦ (passief) | 5.69M | +3.2% | $10.81M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | BlackRock ✦ (passief) | 5.69M | +3.2% | $10.81M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | BlackRock ✦ (passief) | 5.69M | +3.2% | $10.81M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | BlackRock ✦ (passief) | 5.69M | +3.2% | $10.81M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Adage Capital Partners ✦ | 5.28M | -45.2% | $10.03M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | Morgan Stanley ✦ | 4.08M | — | $7.75M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Morgan Stanley ✦ | 4.08M | — | $7.75M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Morgan Stanley ✦ | 4.08M | — | $7.75M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Morgan Stanley ✦ | 4.08M | — | $7.75M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Morgan Stanley ✦ | 4.08M | — | $7.75M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Morgan Stanley ✦ | 4.08M | — | $7.75M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Geode Capital Management ✦ (passief) | 2.39M | -3.0% | $4.54M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | Geode Capital Management ✦ (passief) | 2.39M | -3.0% | $4.54M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 2.37M | -15.2% | $4.51M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 2.37M | -15.2% | $4.51M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 22 | Marshall Wace ✦ | 1.72M | -25.1% | $3.26M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 23 | Marshall Wace ✦ | 1.72M | -25.1% | $3.26M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 24 | Renaissance Technologies ✦ | 1.62M | +10.6% | $3.08M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 25 | Millennium Management ✦ | 1.55M | -59.5% | $2.95M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 26 | JPMorgan Chase ✦ | 1.52M | — | $2.88M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | JPMorgan Chase ✦ | 1.52M | — | $2.88M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | JPMorgan Chase ✦ | 1.52M | — | $2.88M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | JPMorgan Chase ✦ | 1.52M | — | $2.88M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | Citadel Advisors ✦ | 1.43M | +25.3% | $2.72M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 31 | Citadel Advisors ✦ | 1.43M | +25.3% | $2.72M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 32 | State Street Global Advisors ✦ (passief) | 1.11M | +10.6% | $2.11M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 33 | Goldman Sachs Group ✦ | 956.05K | — | $1.82M | 0.0% | n/c | 1 | SEC ↗ |
| 34 | Goldman Sachs Group ✦ | 956.05K | — | $1.82M | 0.0% | n/c | 1 | SEC ↗ |
| 35 | Goldman Sachs Group ✦ | 956.05K | — | $1.82M | 0.0% | n/c | 1 | SEC ↗ |
| 36 | Two Sigma Investments ✦ | 368.11K | -50.9% | $699,403 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 37 | T. Rowe Price ✦ | 140.17K | -15.8% | $267,000 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 38 | Fidelity (FMR) ✦ | 40.35K | -90.9% | $76,665 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 39 | Fidelity (FMR) ✦ | 40.35K | -90.9% | $76,665 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 40 | AQR Capital Management ✦ | 34.95K | Nieuw | $66,409 | 0.0% | New | 1 | SEC ↗ |
| 41 | AQR Capital Management ✦ | 34.95K | Nieuw | $66,409 | 0.0% | New | 1 | SEC ↗ |
| 42 | AQR Capital Management ✦ | 34.95K | Nieuw | $66,409 | 0.0% | New | 1 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| AQR Capital Management | $66,409 | 0.0% |
| AQR Capital Management | $66,409 | 0.0% |
| AQR Capital Management | $66,409 | 0.0% |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 135 houders, 108.23M aandelen, $397.63M gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Vaak gezamenlijk in bezit
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Herkomst: Eigendom op basis van geparseerde 13F common-stockposities (gevolgde universum, vergelijkbare sets voor wijzigingen); insider-rijen afkomstig van formulieren 3/4/5; belangen uit Schedules 13D/13G; elke indiening verwijst naar het origineel op SEC EDGAR.
Rapportageperiode: Q3 2025 ·
Methodologie ·
Verkrijg dit via de API